Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Pancreas. 2012 Nov;41(8):1306–1315. doi: 10.1097/MPA.0b013e31824d64d9

Figure 4.

Figure 4

Apigenin Inhibits NNK-induced ERK activation

BxPC-3 and MIA PaCa-2 and cells were propagated to confluence and then serum-starved overnight prior to treatment. The cells were (A and B) treated with 100 μM of NNK for 0, 1, 5, 10,15 or 30 min, (C) pre-treated with 50 μM of propranolol followed by 100 μM of NNK for 0, 1, 5, 10,15 or 30 min or (D) pre-treated with 50 μM of apigenin followed with 100 μM of NNK for 0, 1, 5, 10,15 or 30 min. The cells were processed for protein and probed with phosphorylated ERK or phosphorylated CREB antibody followed with total ERK or total CREB antibody. Data are presented as relative expression ± SEM based on band densitometry normalized to total ERK or CREB. Statistical significance of p<0.05 are indicated by the asterisk (*) for comparison of BxPC-3 data sets and the double asterisks (**) for comparison of MIA PaCa-2 data sets only.